• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

PEMBROLIZUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • PEMBROLIZUMAB chembl:CHEMBL3137343 ApprovedAntineoplastic

    Alternate Names:

    KEYLYNK-010 COMPONENT PEMBROLIZUMAB
    SCH-900475
    PEMBROLIZUMAB
    PEMBROLIZUMAB COMPONENT OF KEYLYNK-010
    KEYTRUDA
    MK-3475
    LAMBROLIZUMAB
    rxcui:1547545
    pubchem.compound:254741536
    chembl:CHEMBL3137343
    chemidplus:1374853-91-4
    pubchem.substance:254741536
    drugbank:09037

    Drug Info:

    FDA Approval Classical Hodgkin lymphoma, Melanoma, Non-small cell lung cancer (PD-L1+), Head and neck squamous cell carcinoma
    Drug Class Therapeutic Antibodies
    (8 More Sources)

    Publications:

    Zaretsky et al., 2016, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma., N. Engl. J. Med.
    Peng et al., 2016, Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy., Cancer Discov
    McDermott et al., 2015, Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer., Drugs Today
    Dong et al., 2017, Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma., Clin. Cancer Res.
    Shin et al., 2017, Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations., Cancer Discov
    Gainor et al., 2016, EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis., Clin. Cancer Res.
    Skoulidis F et al., 2018, <i>STK11/LKB1</i> Mutations and PD-1 Inhibitor Resistance in <i>KRAS</i>-Mutant Lung Adenocarcinoma., Cancer Discov
    Mehnert et al., 2016, Immune activation and response to pembrolizumab in POLE-mutant endometrial cancer., J. Clin. Invest.
    Johanns et al., 2016, Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy., Cancer Discov
    Gong J et al., 2017, Response to PD-1 Blockade in Microsatellite Stable Metastatic Colorectal Cancer Harboring a <i>POLE</i> Mutation., J Natl Compr Canc Netw
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Zhao J et al., 2019, Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma., Nat Med
    Chen et al., 2017, KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma., Cancer Immunol. Immunother.
    Garon et al., 2015, Pembrolizumab for the treatment of non-small-cell lung cancer., N. Engl. J. Med.
    Aguiar et al., 2017, PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data., Immunotherapy
    Reck et al., 2016, Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer., N. Engl. J. Med.
    Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget
    Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE
    Johnson et al., 2016, Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy., Nat Commun
    Kato et al., 2017, Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate., Clin. Cancer Res.
    Yearley JH et al., 2017, PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer., Clin Cancer Res
    Miao D et al., 2018, Genomic correlates of response to immune checkpoint therapies in clear cell renal cell carcinoma., Science
    Shen J et al., 2018, ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade., Nat Med
  • PEMBROLIZUMAB   PDCD1LG2

    Interaction Score: 2.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28619999


    Sources:
    CIViC

  • PEMBROLIZUMAB   POLE

    Interaction Score: 2.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27159395 27683556 28188185


    Sources:
    CIViC

  • PEMBROLIZUMAB   B2M

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27433843


    Sources:
    CIViC

  • PEMBROLIZUMAB   CD274

    Interaction Score: 1.87

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25891174 28472902 27718847 26918451 26086854


    Sources:
    CIViC PharmGKB FDA

  • PEMBROLIZUMAB   ARID1A

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29736026


    Sources:
    CIViC

  • PEMBROLIZUMAB   MDM4

    Interaction Score: 1.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • PEMBROLIZUMAB   HLA-DRA

    Interaction Score: 0.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26822383


    Sources:
    CIViC

  • PEMBROLIZUMAB   PDCD1

    Interaction Score: 0.8

    Interaction Types & Directionality:
    antibody (inhibitory)
    antagonist (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction Programmed cell death protein 1 inhibitor
    Direct Interaction yes

    PMIDs:
    25685857


    Sources:
    MyCancerGenome ChemblInteractions TTD

  • PEMBROLIZUMAB   PBRM1

    Interaction Score: 0.62

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29301960


    Sources:
    CIViC

  • PEMBROLIZUMAB   JAK1

    Interaction Score: 0.56

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27433843 27903500


    Sources:
    COSMIC CIViC

  • PEMBROLIZUMAB   MDM2

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28351930


    Sources:
    CIViC

  • PEMBROLIZUMAB   CDK12

    Interaction Score: 0.35

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    OncoKB

  • PEMBROLIZUMAB   STK11

    Interaction Score: 0.24

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29773717


    Sources:
    CIViC

  • PEMBROLIZUMAB   ALK

    Interaction Score: 0.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694


    Sources:
    JAX-CKB PharmGKB FDA

  • PEMBROLIZUMAB   JAK2

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type predicted – resistant
    Approval Status Clinical Study

    PMIDs:
    27433843


    Sources:
    JAX-CKB COSMIC CIViC

  • PEMBROLIZUMAB   NRAS

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pembrolizumab + Trametinib
    Indication/Tumor Type melanoma
    Response Type no benefit

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • PEMBROLIZUMAB   PTEN

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type sensitive
    Approval Status Clinical Study

    PMIDs:
    26645196 30742119


    Sources:
    JAX-CKB CIViC

  • PEMBROLIZUMAB   BRAF

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type melanoma
    Response Type no benefit
    Approval Status Preclinical

    PMIDs:
    26645196


    Sources:
    JAX-CKB PharmGKB FDA

  • PEMBROLIZUMAB   EGFR

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type decreased response
    Approval Status Clinical Study

    PMIDs:
    27225694 31086949


    Sources:
    JAX-CKB CIViC PharmGKB FDA

  • PEMBROLIZUMAB   KIT

    Interaction Score: 0.09

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    combination therapy Pembrolizumab + Trametinib
    Indication/Tumor Type melanoma
    Response Type no benefit

    PMIDs:
    28514312


    Sources:
    JAX-CKB

  • PEMBROLIZUMAB   KRAS

    Interaction Score: 0.08

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    28039262 28451792


    Sources:
    JAX-CKB CIViC

  • PEMBROLIZUMAB   TP53

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Indication/Tumor Type non-small cell lung carcinoma
    Response Type predicted – sensitive
    Approval Status Phase I

    PMIDs:
    28039262


    Sources:
    JAX-CKB

  • MyCancerGenome: MK-3475

    • Version: 20-Jun-2017

    Alternate Names:
    MK-3475 Development Name

    Drug Info:
    Drug Class Therapeutic Antibodies

    Publications:

  • MyCancerGenome: PEMBROLIZUMAB

    • Version: 20-Jun-2017

    Alternate Names:
    KEYTRUDA Trade Name

    Drug Info:
    Drug Class Therapeutic Antibodies
    FDA Approval Classical Hodgkin lymphoma, Melanoma, Non-small cell lung cancer (PD-L1+), Head and neck squamous cell carcinoma

    Publications:

  • JAX-CKB: Pembrolizumab

    • Version: 27-September-2017

    Alternate Names:

    Drug Info:

    Publications:
    Zaretsky et al., 2016, Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma., N. Engl. J. Med.
    Zick et al., 2017, Treatment inferred from mutations identified using massive parallel sequencing leads to clinical benefit in some heavily pretreated cancer patients., Medicine (Baltimore)
    Dong et al., 2017, Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma., Clin. Cancer Res.

  • PharmGKB: pembrolizumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

  • CIViC: PEMBROLIZUMAB

    • Version: 14-September-2020

    Alternate Names:

    Drug Info:

    Publications:
    Hastings K et al., 2019, EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer., Ann Oncol
    Passiglia et al., 2016, PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis., Oncotarget
    Carbognin et al., 2015, Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers., PLoS ONE

  • TTD: MK-3475

    • Version: 2020.06.01

    Alternate Names:
    D07DMY TTD Drug ID

    Drug Info:

    Publications:

  • TTD: Pembrolizumab

    • Version: 2020.06.01

    Alternate Names:
    D08ANZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL3137343

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Pembrolizumab

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

  • OncoKB: Pembrolizumab

    • Version: 23-July-2020

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL3137343

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • COSMIC: Pembrolizumab

    • Version: 4-Sep-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21